- Antibiotic developer Motif Bio said it had initiated a rolling submission for a new drug application to the US Food & Drug Administration for a treatment for skin infections.

The submission, for a treatment called iclaprim, was expected to be completed during the second quarter of 2018, the company said.

It had already received a qualified infectious disease product designation from the FDA, together with fast track designation, entitling it to the rolling NDA submission.

Upon NDA approval as a new chemical entity with QIDP designation, iclaprim would be eligible for 10 years of market exclusivity in the US.

At 8:07am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +1.78p at 34.28p

Story provided by